Model of heart dissection, 2 parts
- Known as:
- Model heart dissection, 2 parts
- Catalog number:
- KMA0882
- Product Quantity:
- Set
- Category:
- -
- Supplier:
- Kemaj
- Gene target:
- Model heart dissection 2 parts
Related genes to: Model of heart dissection, 2 parts
- Gene:
- MHRT NIH gene
- Name:
- myosin heavy chain associated RNA transcript
- Previous symbol:
- -
- Synonyms:
- Myheart
- Chromosome:
- 14q11.2
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2014-09-17
- Date modifiied:
- 2017-07-24
Related products to: Model of heart dissection, 2 parts
*Brain Heart CC Agar USE For selective isolation and cultivation of pathogenic fastidious fungi from specimens heavily contaminated with bacteria.1.5-times expansion model of ear dissection, external, middle & internal ear, 4 parts1.5-times expansion model of ear dissection, external, middle & internal ear, 4 parts, 120x60x901.5-times transparent ear model with assistive listening devises1.5-times transparent ear model with assistive listening devises, 1.5 times2 times natural size study model2 times natural size study model, Natural size26 cm model of human body showing chinese acupuncture points26 cm model of human body showing chinese acupuncture points, 110X55x2702D Module for use with Enduro PAGE System, includes capillary tubes and blanking parts2D Module for use with Enduro PAGE System, includes capillary tubes and blanking parts2D Module for use with Enduro PAGE System, includes capillary tubes and blanking parts3 time expansion model of the eyeball, 6 parts, plastic pvc3 time expansion model of the eyeball, 6 parts, plastic pvc, 130x100x1003 times Dental corona model, 15 parts Related articles to: Model of heart dissection, 2 parts
- This study aimed to identify dosimetric and clinical risk factors for ≥Grade 2 radiation pneumonitis (RP) in patients with primary lung cancer undergoing moderately hypofractionated radiotherapy (MHRT). - Source: PubMed
Publication date: 2026/05/09
Yang YuanYouLuo FengXiaWang ChaoRen Gang - Moderately hypofractionated radiation therapy (MHRT) offers practical advantages for postoperative prostate cancer (PC) patients. However, concerns persist regarding long-term genitourinary (GU) toxicity. This prospective cohort study aims to evaluate late toxicities, disease control outcomes, and to identify predictors of late GU toxicity following MHRT. - Source: PubMed
Publication date: 2026/03/21
Ren Xue-YingQin Shang-BinLiu ChaoQi XinBai YunChen Jia-YanLyu FengGao YanLi Xiao-YingLi Hong-ZhenGao Xian-ShuMa Ming-Wei - Moderately hypofractionated radiotherapy (m-HRT) is a standard of care in the radical treatment of localized prostate cancer (PCa). Still, its role after radical prostatectomy (RP) is yet to be defined. We present long-term outcome and toxicity results of m-HRT in the post-prostatectomy setting. - Source: PubMed
Publication date: 2026/04/06
Camilli FedericoCaini SaverioDoccioli ChiaraSaldi SimonettaFesta EleonoraBecchetti Anna GiuliaGravante SabrinaMoretti RiccardoBellavita RitaAristei CynthiaIngrosso Gianluca - To determine the differences in rates of acute and late toxic effects, overall survival (OS), failure-free survival (FFS), and biochemical failure-free survival (BFS) between patients receiving ultra-hypofractionated radiation therapy (UHRT) vs conventionally fractionated radiotherapy (CFRT), UHRT vs moderate hypofractionated radiation therapy (MHRT), or MHRT vs CFRT. - Source: PubMed
Publication date: 2026/03/06
Mo ChunhaoChen ChuanjianFan LeiLi JiaweiFan NingDing Hui - Cervical cancer (CC) remains a leading cause of cancer-related mortality, particularly in low- and middle-income countries (LMICs), despite advancements in HPV vaccination and screening. Radiotherapy (RT) plays a critical role in managing CC, but conventional fractionated radiotherapy (CFRT) is limited by long treatment durations, which reduce patient adherence, increase the risk of treatment interruptions, and impair healthcare access in LMICs. Moderately hypofractionated radiotherapy (MHRT) may offer a promising alternative, delivering higher doses per fraction with fewer total fractions, thus shortening treatment duration and alleviating the burden on both patients and healthcare systems. Early clinical data suggest that MHRT achieve acceptable short- to medium-term tumor control with manageable toxicity. However, the small sample sizes and limited follow-up in published studies preclude definitive conclusions about long-term efficacy and safety. This review synthesizes the existing clinical evidence to outline the potential benefits and inherent limitations of MHRT in CC management and highlight the need for future large-scale, long-term randomized controlled trials with rigorous quality assurance protocols. These findings also have implications for the potential implementation of MHRT in LMICs. - Source: PubMed
Publication date: 2026/01/01
Xiao HuiGuo FuxinWang ZhenyuPei KangjiaWei ShuhuaQu AngWang JunjieJiang Ping